Combination therapy for multiple sclerosis with traditional Chinese medicine
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether adding a traditional Chinese herbal formula to standard multiple sclerosis (MS) treatments helps reduce MS activity. It aims to see if the combination is more effective than medication alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of relapsing-remitting multiple sclerosis (RRMS).
- You have not had a relapse (flare-up) in the last 30 days.
- You must be currently taking one of the approved first-line disease-modifying therapies (DMTs) at a stable dose.
- You must be able to undergo MRI scans (including with contrast).
- You are not pregnant, breastfeeding, or participating in another trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a traditional Chinese medicine (Yishen Daluo Yin granules) for people with relapsing-remitting multiple sclerosis (MS), the most common form where symptoms come and go. The goal is to see if this herbal treatment can reduce relapses and is safe to use.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
Hear when a new RRMS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.